Filing Flows

Filing Flows › Companies › Black Diamond Therapeutics › Cash flow

Black Diamond Therapeutics cash flow, quarter by quarter

Latest: Q2 2026 · from the cash-flow statements filed with the SEC

Free cash flow−$8.0M in Q2 2026 · −$32.8M over twelve months

Operating cash flow−$8.0M
Free cash flow−$8.0M

Analysis

In Q2 2026, Black Diamond Therapeutics generated −$8.0M of operating cash flow. That is $1.2M more than in Q2 2025 (−$9.2M).

Over the twelve months to Jun 30, 2026, operating cash flow was −$32.8M; the largest uses were operating cash flow ($32.8M), other financing ($30K); besides operations, cash came from other investing ($22.1M), asset & business sales ($4K); the cash balance fell by $10.8M.

Operating cash flow was −$8.0M against net income of −$9.9M. The largest differences: accrued liabilities +$2.9M, payables −$1.6M, stock-based pay +$1.5M.

Free cash flow

Black Diamond Therapeutics: free cash flow by quarterBlack Diamond Therapeutics: free cash flow by quarter−$11.3MQ3 2024−$15.1MQ4 2024$53.4MQ1 2025−$9.2MQ2 2025−$7.8MQ3 2025−$6.8MQ4 2025−$10.2MQ1 2026−$8.0MQ2 2026
Operating cash flow less capital spending.
Black Diamond Therapeutics: operating cash flow against capital spendingBlack Diamond Therapeutics: operating cash flow against capital spendingOperating cash flowCapital spending−$11.3M$0Q3 2024−$15.1M$0Q4 2024$53.4M$0Q1 2025−$9.2M$0Q2 2025−$7.8M$0Q3 2025−$6.8M$0Q4 2025−$10.2M$0Q1 2026−$8.0M$0Q2 2026
Latest (Q2 2026): Operating cash flow −$8.0M, Capital spending $0.

Capital allocation, year by year

Black Diamond Therapeutics: where the cash came from (up) and went (down), by fiscal yearBlack Diamond Therapeutics: where the cash came from (up) and went (down), by fiscal yearOperating cash flowShares issuedAsset salesCapital spendingFY2021: Operating cash flow −$100MFY2021: Shares issued $729KFY2021: Capital spending −$2.7M$729KFY2021FY2022: Operating cash flow −$85.1MFY2022: Shares issued $177KFY2022: Asset sales $9KFY2022: Capital spending −$192K$186KFY2022FY2023: Operating cash flow −$66.7MFY2023: Shares issued $71.9MFY2023: Asset sales $95KFY2023: Capital spending −$33K$72.0MFY2023FY2024: Operating cash flow −$62.3MFY2024: Shares issued $25.5MFY2024: Asset sales $94K$25.6MFY2024FY2025: Operating cash flow $29.6MFY2025: Asset sales $27K$29.6MFY2025
Over these 5 years operating cash flow totalled −$285M; the largest uses were operating cash flow ($314M) and capital spending ($2.9M). Cash-flow statements as filed.

Where the cash came from and went

Black Diamond Therapeutics: sources (+) and uses (−) of cash, Q2 2026Black Diamond Therapeutics: sources (+) and uses (−) of cash, Q2 2026Cash drawn (+) / kept (−)$10.9MOperating cash flow−$8.0MOther investing−$3.1MOther financing$217K
Black Diamond Therapeutics: sources (+) and uses (−) of cash, TTM to Q2 2026Black Diamond Therapeutics: sources (+) and uses (−) of cash, TTM to Q2 2026Operating cash flow−$32.8MOther investing$22.1MCash drawn (+) / kept (−)$10.8MOther financing−$30KAsset & business sales$4K

From profit to cash

Black Diamond Therapeutics: net income to operating cash flow, Q2 2026Black Diamond Therapeutics: net income to operating cash flow, Q2 2026Net income−$9.9MDepreciation & amortization$28KStock-based pay$1.5MPayables−$1.6MAccrued liabilities$2.9MPrepaid and other assets−$42KOperating cash flow−$8.0M
Non-cash charges are added back; money tied up in receivables or inventory is subtracted.

Every quarter

QuarterOperating cash flowShares issuedCash drawn (+) / kept (−)Free cash flow
Q2 2026−$8.0M—$10.9M−$8.0M
Q1 2026−$10.2M—−$9.1M−$10.2M
Q4 2025−$6.8M—$9.9M−$6.8M
Q3 2025−$7.8M—−$874K−$7.8M
Q2 2025−$9.2M—$68.4M−$9.2M
Q1 2025$53.4M$32K−$62.0M$53.4M
Q4 2024−$15.1M$291K−$13.0M−$15.1M
Q3 2024−$11.3M−$252K$9.4M−$11.3M

Black Diamond Therapeutics: income statement and cash flow

Black Diamond Therapeutics, Q1 2025: revenue $70.0M, operating margin 77.9%. The chart follows the revenue to costs, profit and cash.

Black Diamond Therapeutics: every quarter, Q/Q and Y/Y → Open in the app

Read automatically from the company’s XBRL cash-flow statements; quarterly figures for the fourth quarter are the year less the first three. Errors are possible. Not investment advice.